November 5, 2026

The Manager - Listing
BSE Limited
P J Towers, Dalal Street, Fort
Mumbai - 400 001

The Manager - Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting held on Thursday, November 5, 2026

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 of the and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby inform that at its meeting held today, i.e. on Thursday, November 5, 2026, the Board of Directors ('Board') has, *inter alia*, considered and approved the following:

1. **Unaudited Financial Results**

   The Unaudited Financial Results of the Company for the quarter and half – year ended September 30, 2026. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors are enclosed herewith.

   Further, we are arranging to publish the above-mentioned financial results in newspapers as per Regulation 47 of the SEBI Listing Regulations.

2. **Appointment of Mr. Krishnamurthy Narayanan Iyer as an Additional Director (Independent) of the Company**

   Based on the recommendation of the Nomination and Remuneration Committee ('NRC'), the Board has approved the appointment of Mr. Krishnamurthy Narayanan Iyer (DIN: 01726564) as an Additional Director of the Company with effect from November 5, 2026, to hold office as a Non- Executive, Independent Director, not liable to retire by rotation, for a term of five (5) consecutive years, subject to approval of the shareholders of the Company.

3. **Appointment of Mr. Atul Tandon as Chief Financial Officer of the Company**

   Based on the recommendation of the NRC and the Audit Committee, the Board has approved the appointment of Mr. Atul Tandon as Chief Financial Officer (i.e. a Key Managerial Personnel as defined in the Companies Act, 2013), with effect from November 9, 2026.

4. **Change in designation of Mr. Nitin Bindal (Senior Management Personnel) to Director - Biopharmaceuticals Business Unit**

   Further to our communication dated January 9, 2026, intimating about the appointment of Mr. Nitin Bindal as Director - Institutional Business & Public Channels, we hereby inform about a change in his role to Director - Biopharmaceuticals Business Unit, with effect from November 9, 2026. Mr. Bindal continues to be a Senior Management Personnel of the Company. Consequent to this role change, the Institutional Business and Public Channel functions, will revert to the Oncology Business Unit.

5. **Appointment of Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit**

   Based on the recommendation of the NRC, the Board has approved the appointment of Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit (Senior Management Personnel) with effect from December 1, 2026.

The details for the above appointments / change in SMP role as required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure - A.

The above information is also being made available on the website of the Company at www.astrazeneca.com/india.

The meeting of the Board of Directors commenced at 1.30 p.m. and concluded at 3.50 p.m.

Kindly take the above information on record.

Thanking you,

For AstraZeneca Pharma India Limited

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.11.05 17:34:28 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No. A25784

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of unaudited financial results for the quarter and half year ended 30th September 2026

'Rs in millions except for earnings per share data

Sl No.	Particulars	Quarter ended			Half-year ended		Year ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	a) Revenue from operations	7,291.0	6,827.9	5,590.9	14,118.9	10,854.0	22,755.8
	b) Other income	151.2	92.3	61.7	243.5	174.1	284.9
	Total income	**7,442.2**	**6,920.2**	**5,652.6**	**14,362.4**	**11,028.1**	**23,040.7**
2	**Expenses**						
	(a) Cost of materials consumed	-	-	-	-	94.9	94.9
	(b) Purchase of stock-in-trade	6,241.0	3,046.2	4,324.0	9,287.2	8,499.9	18,594.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,502.5)	1,425.9	(1,079.1)	(76.6)	(2,395.8)	(4,883.7)
	(d) Employee benefit expense	678.5	791.6	604.5	1,470.1	1,249.0	2,643.8
	(e) Finance costs	18.9	19.5	6.7	38.4	13.9	44.9
	(f) Depreciation and amortisation expense	53.5	52.3	25.7	105.8	191.4	285.8
	(g) Selling, marketing and distribution expense	177.0	307.5	280.1	484.5	500.3	1,160.0
	(b) Other expenses	741.3	767.3	709.6	1,508.6	1,342.8	2,526.3
	Total expenses	**6,407.7**	**6,410.3**	**4,871.5**	**12,818.0**	**9,496.4**	**20,466.2**
3	**Profit before exceptional items and tax (1-2)**	**1,034.5**	**509.9**	**781.1**	**1,544.4**	**1,531.7**	**2,574.5**
4	Add/(Less): Exceptional items (Refer Note 3,4,5)	(149.6)	(2.4)	(52.9)	(152.0)	(56.5)	(52.5)
5	**Profit before tax (3+4)**	**884.9**	**507.5**	**728.2**	**1,392.4**	**1,475.2**	**2,522.0**
6	**Tax expense**						
	(a) Current tax	250.3	108.7	190.1	359.0	411.1	591.4
	(b) Tax expense for prior years	-	-	-	-	-	2.8
	(c) Deferred tax charge / (credit)	11.3	19.5	(4.1)	30.8	(36.4)	52.6
	Total tax expense (net)	**261.6**	**128.2**	**186.0**	**389.8**	**374.7**	**646.8**
7	**Profit after tax (5-6)**	**623.3**	**379.3**	**542.2**	**1,002.6**	**1,100.5**	**1,875.2**
8	**Other comprehensive (loss) / Income** Items that will not be reclassified to profit or loss						
	(a) Re-measurement (losses)/ gains on post employment benefit obligations	(3.7)	(4.0)	(4.1)	(7.7)	4.1	(59.4)
	(b) Income tax effect on above	0.9	1.0	1.1	1.9	(1.0)	15.0
	Other comprehensive (loss)/ income,net of income tax	**(2.8)**	**(3.0)**	**(3.0)**	**(5.8)**	**3.1**	**(44.4)**
9	**Total comprehensive income for the period/ year (7+8)**	**620.5**	**376.3**	**539.2**	**996.8**	**1,103.6**	**1,830.8**
10	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**50.0**	**50.0**	**50.0**	**50.0**	**50.0**	**50.0**
11	**Other Equity**	-	-	-	-	-	8,677.9
12	**Earnings per equity share of Rs 2/- each (basic and diluted) *Not annualised**	**24.93***	**15.17***	**21.69***	**40.10***	**44.02***	**75.01**

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

AstraZeneca Pharma India Ltd.
Mumbai
63.

AstraZeneca Pharma India Limited

Statement of unaudited assets and liabilities

Rs in millions

Sl.No.	Balance Sheet	As at	
		30-09-2026	31-03-2026
		Unaudited	Audited
	ASSETS		
1	**Non-current assets**		
	(a) Property, plant and equipment	31.2	46.7
	(b) Right-of-use assets	959.3	1,128.0
	(c) Capital work-in-progress	155.9	-
	(d) Financial Assets		
	(i) Other financial assets	113.7	134.1
	(e) Non-Current tax assets (net)	888.1	789.2
	(f) Deferred tax assets (net)	349.3	378.0
	(g) Other non-current assets	14.2	15.7
	Total Non-current assets	**2,511.7**	**2,491.7**
2	**Current assets**		
	(a) Inventories	10,350.0	10,273.3
	(b) Financial Assets		
	(i) Trade receivables	2,850.0	2,136.8
	(ii) Cash and cash equivalents	5,738.1	4,477.2
	(iii) Bank balances other than cash and cash equivalents	13.3	9.0
	(iv) Loans	-	-
	(v) Other financial assets	114.4	87.4
	(c) Other current assets	300.4	338.2
	Total Current assets	**19,366.2**	**17,321.9**
3	**Assets classified as held for sale (Refer note 3)**	**36.1**	77.4
	TOTAL ASSETS	**21,914.0**	**19,891.0**
	EQUITY AND LIABILITIES		
1	**Equity**		
	(a) Equity Share capital	50.0	50.0
	(b) Other Equity	8,739.2	8,677.9
	TOTAL EQUITY	**8,789.2**	**8,727.9**
	LIABILITIES		
2	**Non-current liabilities**		
	(a) Financial Liabilities		
	(i) Lease liabilities	839.3	967.5
	(b) Provisions	203.8	158.3
	(c) Other non-current liabilities	186.6	219.2
	Total Non-current liabilities	**1,229.7**	**1,345.0**
3	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Lease liabilities	122.8	139.1
	(ii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	34.5	20.4
	Total outstanding dues of creditors other than micro enterprises and small enterprises	9,722.9	7,806.6
	(iii) Other financial liabilities	267.6	228.2
	(b) Other current liabilities	1,189.1	1,010.5
	(c) Provisions	504.1	559.2
	(d) Current tax liabilities (net)	54.1	54.1
	Total Current liabilities	**11,895.1**	**9,818.1**
	TOTAL LIABILITIES	**13,124.8**	**11,163.1**
	TOTAL EQUITY AND LIABILITIES	**21,914.0**	**19,891.0**

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

AstraZeneca Pharma India Ltd.
Mumbai
63.

AstraZeneca Pharma India Limited

Statement of unaudited cash flows

Rs in millions

Particulars	Half-year ended	
	30-09-2026	30-09-2025
	Unaudited	Unaudited
A) Cash flow from operating activities		
Profit before tax	**1,392.4**	**1,475.2**
Non-cash adjustments for :		
Depreciation and amortisation expense	105.8	191.4
Net gain on sale/disposal of property, plant and equipment	(31.0)	(0.4)
Provision for restructuring costs/severance costs	(4.1)	57.1
Impairment of other assets	3.2	-
Interest income on deposits carried at amortised cost	(109.0)	(137.5)
Other operating income	(3.1)	-
Employee stock compensation expense	(0.7)	5.8
Unrealised foreign exchange gain (net)	(1.1)	(7.7)
Allowance for expected credit loss (net)	90.0	76.6
Finance costs	38.4	13.9
Operating profit before working capital changes	**1,480.8**	**1,674.4**
Changes in working capital:		
(Increase) in trade receivables	(802.1)	(422.8)
(Increase) in inventories	(76.7)	(2,301.2)
Decrease in loans	-	1.6
(Increase)/ Decrease in other financial assets	(2.6)	61.4
Decrease in other assets	39.4	176.0
Increase in trade payables	1,930.4	946.1
(Decrease) in provisions	(13.2)	(130.8)
Increase in other financial liabilities	2.1	10.3
Increase/ (Decrease) in other liabilities	223.6	(239.3)
Cash generated from operations	**2,781.7**	**(224.3)**
Income taxes paid (net of refund)	(457.9)	(433.0)
Net cash generated from / (used in) operating activities (A)	**2,323.8**	**(657.3)**
B) Cash flows from investing activities		
Interest income on bank deposits	100.7	136.9
Purchase of property, plant and equipment, intangible assets and capital work in progress	(155.9)	(2.9)
Proceeds from sale of property, plant and equipment	-	1.4
Net cash (used in) /generated from investing activities (B)	**(55.2)**	**135.4**
C) Cash flows from financing activities		
Principal repayment of lease liabilities	(69.3)	(31.7)
Interest paid on lease liabilities	(38.3)	(13.8)
Interest paid - others	(0.1)	(0.1)
Dividend paid	(900.0)	(800.0)
Net cash used in financing activities (C)	**(1,007.7)**	**(845.6)**
D) Net increase / (decrease) in cash and cash equivalents (A+B+C)	**1,260.9**	**(1,367.5)**
E) Cash and cash equivalents at the beginning of the year	**4,477.2**	**5,361.4**
F) Cash and cash equivalents at the end of the period (D+E)	**5,738.1**	**3,993.9**
Non-cash investing activities		
- Acquisition of right-of-use assets	-	778.5
- Disposal of right-of-use-assets	139.6	-

Components of cash and cash equivalents as at the end of the period	As at 30 Sep 2026	As at 30 Sep 2025
Balance with banks :		
Current accounts	162.1	226.6
Demand deposits with original maturity of less than 3 months	5,576.0	3,767.3
Cash in transit	-	
Total cash and cash equivalents	**5,738.1**	**3,993.9**

Note: The above statement of cashflow has been prepared under the 'Indirect Method' as set out in Indian Accounting Standard (Ind AS) 7- Statement of Cash Flows.

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

AstraZeneca Pharma India Ltd.
Mumbai
63

AstraZeneca Pharma India Limited
Statement of unaudited financial results for the quarter and half year ended 30th September 2026

Notes:

1 The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the "Act") [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided.

3 Exceptional items:

a Exceptional items for the quarter ended 30 September 2026 , 30 June 2026 and 30 September 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 4 below)

b The exceptional items for the quarter and half year ended 30 September 2026 consists of BBMP interest (Refer note 5 below)

4 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. The cost, [(charge)/ reversal] related to closure of manufacturing site included in exceptional item is Rs. 6.5, Rs. (2.4), Rs. (52.9), Rs. 4.1, Rs. (56.5) and Rs. (52.5) for the quarter ended September 30, 2026, June 30, 2026, September 30, 2025, for the half year ended September 30, 2026, September 30, 2025 and full year March 31, 2026 respectively.

5 The Company had received a notice from Bruhat Bangalore Mahanagara Palike (BBMP) on 7 August 2014, followed by reminder notices, demanding Rs. 70.8 (2026: Rs. 70.8) as improvement charges for its factory land and had recorded a provision against this demand in the earlier years. Following the final judgement of the High Court of Karnataka holding that the property falls within the jurisdictional limits, the Company intends to settle the matter. During the current period, based on the Company's assessment and information available to date , a provision of Rs. 156.1 towards interest relating to the aforesaid improvement charges has been recognised and has been presented as an exceptional item. The provision represents the Company's current estimate of probable outflow and will be reassessed based on the ultimate determination/ outcome of the matter.

6 During the current year , the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Subsequent to the quarter end, the Company received a reminder notice on 05 October 2026 for Rs. 1,511.96, including interest calculated till 30 October 2026. Pursuant to the writ petition filed by the company, the Hon'ble High Court vide its order dated 29 October 2026 has directed that no coercive steps be taken by NPPA in respect of collection of the amount demanded till the next date of hearing i.e. listed on 11 January, 2027. Based on assessment, supported by external legal advice, Management has concluded that it has reasonable grounds to defend its position. Accordingly, no provision has been made in these financial statements.

7 This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 05 November 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

For and on behalf of the Board of Directors
For AstraZeneca Pharma India Limited

Praveen Rao Akkinepally
Managing Director

AstraZeneca Pharma India Ltd. Mumbai 63.

Place: Mumbai
Date: 05th November, 2026

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited financial results of AstraZeneca Pharma India Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of AstraZeneca Pharma India Limited

1. We have reviewed the accompanying Statement of unaudited financial results of AstraZeneca Pharma India Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The financial results of the Company for the year ended 31 March 2026 were audited by the predecessor auditor whose report dated 26 May 2026 had expressed an unmodified opinion. The financial results of the Company for the corresponding quarter ended 30 September 2025 and the corresponding period from 1 April 2025 to 30 September 2025 were reviewed by the predecessor auditor whose report dated 07 November 2025 had expressed an unmodified conclusion.

Limited Review Report *(Continued)*

AstraZeneca Pharma India Limited

6. The financial results of the Company for the three months ended 30 June 2026 were reviewed by the predecessor auditor whose report dated 10 August 2026 had expressed an unmodified conclusion

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Sreeja Marar

Partner

Membership No.: 111410

UDIN:26111410AJLHOT9084

Mumbai

05 November 2026

Annexure - A

Sl. No.	Particulars	Mr. Krishnamurthy Narayanan Iyer as Additional Director (Non-Executive, Independent)	Mr. Atul Tandon as Chief Financial Officer	Mr. Nitin Bindal as Director - Biopharmaceuticals Business Unit	Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Krishnamurthy Narayanan Iyer (DIN: 01726564) as an Additional Director (Non-Executive, Independent)	Appointment as Chief Financial Officer	Change in role/designation of SMP	Appointment as SMP
2	Date of appointment/ cessation (as applicable) and term of appointment	November 5, 2026 Term: For a period of five (5) years commencing from November 5, 2026	Effective November 9, 2026 Term: Full-time employment	Effective November 9, 2026 Term: Full-time employment	Effective December 1, 2026 Term: Full-time employment
3	Brief Profile	Mr. Iyer has over four decades of leadership experience across retail, consumer products, banking and financial services, in India and internationally. He is a Chartered Accountant and a Company Secretary, and holds a Bachelor of Commerce (Honours) degree from Sydenham College of Commerce &	Atul Tandon led AstraZeneca Vietnam Company Ltd. as Chairman and General Director December 2023. Under his leadership, AstraZeneca in Vietnam doubled its revenue, consistently outperformed market 2x-3x and achieved #1 rank in each Therapeutic	Nitin has over 17 years of diverse experience in the pharmaceutical industry across multiple therapeutic areas and functions. In a distinguished career at Bristol Myers Squibb (BMS), Nitin served as	Kumaran Krishnan is an accomplished Global Medical Affairs leader with extensive experience in shaping medical strategy, leading new product launches, and advancing digital innovation and transformation

Sl. No.	Particulars	Mr. Krishnamurthy Narayanan Iyer as Additional Director (Non-Executive, Independent)	Mr. Atul Tandon as Chief Financial Officer	Mr. Nitin Bindal as Director - Biopharmaceuticals Business Unit	Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit
		Economics, Mumbai. Mr. Iyer was Managing Director, President & CEO of Walmart India from 2014 to 2020. In that role he led the business's long-term strategy, its move towards omnichannel retail, and the turnaround of the Best Price Cash & Carry business. He also played a significant role in Walmart's 2018 acquisition of a majority stake in Flipkart. Before that, he was Senior Vice President at Walmart International, where he worked on special projects including a stint with Walmart Japan. From 2006 to 2012, he held senior leadership roles as Managing Director & Country Head at A.S. Watson, leading its health	Area of presence, leveraging its # 1 rank in reputation across ecosystem and its position as Asia's Best Company to Work. He has been associated with AstraZeneca Group since 2011 and during this time, he has led teams in Finance, Strategy, Business Development and business units in Diabetes and Oncology. Prior to his transition to Vietnam, Atul was responsible for Bio-Pharma Business for Asia Area, based in Singapore. Atul has around 26 years of diversified industry experience, including with conglomerates like	Business Unit Director – Oncology & Haematology, where he led access and market penetration for immunotherapies across 20 indications. Prior to BMS, Nitin spent over eight years at Johnson & Johnson (J&J), where he held key roles including National Sales Head and Senior Marketing Manager in Oncology, and led the Neuroscience Business Unit. Before J&J he has significantly contributed to strategy and commercial roles at organisations such as	across Europe and international markets, including China and Japan. Born and raised in India, Kumaran trained as a clinical pharmacist, subsequently relocated to the United Kingdom, where he attained a Master of Business Administration in Aberdeen, studied health economics in Oxford, and undertook an MSc module in diabetes and obesity in Surrey. Most recently, as part of AstraZeneca's leadership

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Sl. No.	Particulars	Mr. Krishnamurthy Narayanan Iyer as Additional Director (Non-Executive, Independent)	Mr. Atul Tandon as Chief Financial Officer	Mr. Nitin Bindal as Director - Biopharmaceuticals Business Unit	Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit
		and personal care retail businesses in Thailand, Taiwan and the Philippines. Mr. Iyer is an Independent Director of Procter & Gamble Hygiene and Healthcare Limited (PGHH) and Gillette India Limited, and serves on Audit and Risk Management Committees of PGHH. He is Chairman of Rational Equity Partners LLP. He has been Chairman of the American Chamber of Commerce in India and has chaired the FICCI Retail Committee. He brings expertise in strategy, financial oversight, risk management, governance, consumer markets, digital transformation and stakeholder engagement.	Aditya Birla Group and ITC Ltd. During his stint at ITC, Atul was associated with its unique socio-economic initiative, E-Choupal. Atul also has had a brief stint with a boutique research and advisory firm, Boston Analytics as Vice President, during which he executed projects for globally renowned CPG Companies on emerging market strategies and Organization re-design. Atul is a Chartered Accountant and an MBA from the Indian School of Business, Hyderabad.	Novartis, Wockhardt, and Smart Analyst. He holds a degree in Chemical Engineering from IIT Bombay and a Post Graduate Program in Management for Executives from UCLA Anderson School of Management (Los Angeles, CA, USA).	development initiative, he completed the Executive Leadership Program at Wharton Executive Education, USA. Throughout his pharmaceutical career spanning more than three decades, Kumaran has remained deeply committed to improving patient care. He has successfully delivered more than 20 new product launches across multiple therapy areas while working with leading organisations, including

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Sl. No.	Particulars	Mr. Krishnamurthy Narayanan Iyer as Additional Director (Non-Executive, Independent)	Mr. Atul Tandon as Chief Financial Officer	Mr. Nitin Bindal as Director - Biopharmaceuticals Business Unit	Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit
					Merck, Pfizer, Sanofi and Teva. Kumaran joined AstraZeneca in 2021, where he led EUCAN regional medical strategy and operations and championed the transformation of Medical Information. More recently, as Europe & Canada (EUCAN) Regional Medical Director, he played an instrumental role in leading pre-launch activities for Baxdrostat and assets in the weight management portfolio.

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Sl. No.	Particulars	Mr. Krishnamurthy Narayanan Iyer as Additional Director (Non-Executive, Independent)	Mr. Atul Tandon as Chief Financial Officer	Mr. Nitin Bindal as Director - Biopharmaceuticals Business Unit	Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit
					Over the course of his career, Kumaran has held positions of increasing responsibility, progressing from leadership of the UK medical team to regional and global roles.
4	Disclosure of relationships between directors	Mr. Iyer is not related to any of the Directors of the Company	Not Applicable	Not Applicable	Not Applicable

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628